A phase IV study to evaluate the primary and booster immune responses of UK infants receiving a licensed 6-in-1 DTaP/IPV/Hib/HBV vaccine (Infanrix-HexaTM) with a 13-valent pneumococcal conjugate vaccine and incorporating a randomisation study of a single dose of 3 different meningococcal group C conjugate vaccines at 3 months of age
Phase of Trial: Phase IV
Latest Information Update: 18 Mar 2019
At a glance
- Drugs Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa) (Primary) ; Hib-meningococcal vaccine group C conjugate; Measles mumps and rubella virus vaccine-(Priorix); Meningococcal vaccine group C conjugate; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Hepatitis B
- Focus Pharmacodynamics
- Acronyms Infanrix-Hexa
- 15 Mar 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 04 Apr 2017 Status changed from active, no longer recruiting to completed.
- 15 Jun 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2016.